Albireo Pharma (ALBO) Rating Reiterated by Wedbush

Albireo Pharma (NASDAQ:ALBO)‘s stock had its “buy” rating restated by analysts at Wedbush in a report released on Wednesday. Wedbush also issued estimates for Albireo Pharma’s FY2022 earnings at $7.44 EPS.

The analysts wrote, “Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders.””

Other equities analysts have also recently issued research reports about the stock. ValuEngine cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Thursday, October 26th. Roth Capital began coverage on shares of Albireo Pharma in a research report on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price target on the stock. Zacks Investment Research cut shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Finally, Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $53.75.

Shares of Albireo Pharma (NASDAQ:ALBO) traded up $1.79 during midday trading on Wednesday, reaching $29.08. 49,300 shares of the company traded hands, compared to its average volume of 28,933. Albireo Pharma has a twelve month low of $15.31 and a twelve month high of $29.63.

In other Albireo Pharma news, major shareholder Plc Astrazeneca sold 500,000 shares of Albireo Pharma stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $21.40, for a total transaction of $10,700,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 22.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2018/01/05/albireo-pharma-albo-rating-reiterated-by-wedbush.html.

About Albireo Pharma

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply